Albumin Dosing in AKI with Hepatorenal Syndrome
For adults with AKI and cirrhosis, administer albumin 1 g/kg/day (maximum 100 g/day) for 2 consecutive days when serum creatinine doubles from baseline, followed by 20-40 g daily if hepatorenal syndrome (HRS-AKI) is diagnosed and creatinine remains elevated. 1, 2
Initial Management: Stage 1-2 AKI
When AKI is first diagnosed in a cirrhotic patient:
- Withdraw diuretics, NSAIDs, and nephrotoxic drugs immediately
- Administer albumin 1 g/kg/day for 2 days if serum creatinine shows doubling from baseline 1, 2
- Maximum daily dose should not exceed 100 g 2
- This serves both as treatment and diagnostic challenge to differentiate volume-responsive AKI from HRS-AKI
Treatment of Confirmed HRS-AKI (Stage 2-3)
If creatinine remains >2× baseline after initial 2-day albumin challenge:
Day 1:
Subsequent days:
- Albumin 20-40 g daily 1, 2
- Continue until creatinine returns to ≤0.3 mg/dL above baseline for 2 consecutive days, or for maximum 14 days 1
- Always combine with vasoconstrictors (terlipressin, norepinephrine, or midodrine/octreotide) 1
Infusion Duration and Monitoring
Critical safety consideration: The standard dose (1.5 g/kg day 1 g/kg day 3) infused over 6 hours is poorly tolerated in many patients, with high rates of circulatory overload 3. The most recent evidence shows:
- Infuse albumin over prolonged periods (not specified in guidelines, but >6 hours based on safety data)
- Monitor closely for pulmonary edema—this is the primary risk 1, 4
- Stop infusion immediately if respiratory distress develops 3
- Use clinical assessment of volume status (vital signs, urine output, echocardiography, or CVP if central line present) 1
Context-Specific Dosing
For spontaneous bacterial peritonitis (SBP) with AKI:
- 1.5 g/kg within 6 hours of diagnosis
- 1 g/kg on day 3 1, 5
- Particularly beneficial if baseline creatinine >1.0 mg/dL or bilirubin >4 mg/dL 6, 5
For large-volume paracentesis (>5L):
- 8 g albumin per liter of ascites removed 7, 4
- Consider this dose even for <5L if patient has ACLF or high AKI risk 7
Important Caveats
General AKI without cirrhosis: Albumin is not recommended for routine volume expansion in AKI. The 2013 KDIGO guidelines explicitly suggest using isotonic crystalloids rather than colloids (including albumin) as initial management 8. This is a grade 2B recommendation.
Exceptions where albumin is appropriate:
- Cirrhosis with complications (as detailed above)
- Hepatorenal syndrome diagnostic criteria require albumin challenge 8
Avoid albumin in:
- Traumatic brain injury (associated with harm) 8
- General critical illness without cirrhosis 4
- Cardiac surgery (recent 2026 meta-analysis shows increased AKI risk with 20-25% albumin) 9
Practical Algorithm
- Diagnose AKI stage (creatinine rise ≥0.3 mg/dL in 48h or ≥1.5× baseline)
- Remove precipitants (diuretics, nephrotoxins)
- If creatinine doubled: Give albumin 1 g/kg/day × 2 days (max 100 g/day)
- Reassess at 48 hours:
- If improved: Continue monitoring
- If creatinine remains >2× baseline: Diagnose HRS-AKI
- For HRS-AKI: Albumin 1 g/kg day 1, then 20-40 g daily + vasoconstrictors
- Continue until: Creatinine ≤0.3 mg/dL above baseline × 2 days OR 14 days maximum
The evidence strongly supports this approach specifically for cirrhotic patients, where albumin serves multiple functions beyond volume expansion, including anti-inflammatory effects and binding of vasoactive substances 1, 2. However, the general AKI population should receive crystalloids as first-line therapy 8.